Accretion Nutraveda Ltd

Accretion Nutraveda IPO

Accretion Nutraveda Ltd

₹2,44,000 /2000 sharesMinimum investment

IPO listing details

Listed on
4 Feb '26
Issue price
₹129.00
Listing price
₹191.00
Listing gains
₹62.00 (48.06%)
Exchange
--

IPO details

Minimum investment
₹2,44,000
Price range
₹122 - ₹129
Lot size
1,000
Issue size
24.77 Cr
Face value
10
IPO document

Subscription rate

Qualified Institutional Buyers1.01x
Non-Institutional Investor1.80x
Retail Individual Investor2.19x
Total1.77x
As of 30 Jan'26, 05:01 PM

Schedule

28 Jan 2026
IPO open date
30 Jan 2026
IPO close date
2 Feb 2026
Allotment date
2 Feb 2026
Funds unblock or debit
4 Feb 2026
Tentative listing date

About

Accretion Nutraveda Limited manufactures Ayurvedic and nutraceutical products and functions as a contract development and manufacturing organisation, serving domestic and export markets. It makes tablets, capsules, oral liquids, oral powders, external preparations, and oils. Tablets include film-coated and chewable varieties used in liver care, gynaecological care, bone and joint health, and respiratory support. Capsules include hard gelatin and HPMC formats for liver detoxification, women’s health, and cognitive support. Oral liquids include syrups, suspensions, and tonics for paediatric and geriatric use. It also produces churan powders, medicated Ayurvedic oils, and external balms, ointments, creams, and gels for pain relief, skin care, and hair care. The company runs a leased, two-floor manufacturing facility with 13 HEPA-filter air handling units and segregated processing and dispensing areas to limit cross-contamination.;
Founded in
2021
MD/CEO
Mr Mayur Popatlal Sojitra
Parent organisation
Accretion Nutraveda Ltd

Accretion Nutraveda Financials

Revenue
Total Assets
Profit
All values are in ₹ Cr
2.905.0016.00202320242025

Strengths & Risks

Strengths
Risks
Accretion Nutraveda Limited claims to have a product portfolio of over 72 formulations across Ayurvedic and nutraceutical segments. Its manufacturing capabilities span tablets, capsules, oral liquids, churans, oils, and multiple external preparations, covering therapeutic and wellness-focused applications. This range allows it to cater to varied formulation and dosage requirements under a single manufacturing setup.
The company’s manufacturing facility is stated to be WHO-GMP approved and certified under ISO 9001:2015 for its quality management systems and ISO 45001:2018 for occupational health and safety.
The company claims to have built ongoing relationships with clients and suppliers, overseen directly by its promoters. These relationships support the sourcing of raw materials, distribution activities, and operational continuity. Management involvement in these engagements is presented as a key operational feature.
Accretion Nutraveda claims to have formal business processes covering supply chain management, service delivery, and regulatory compliance. Its management and governance framework is stated to support scalability and operations across domestic and export markets.
The company has witnessed a consistent increase in its revenue from operations and profit after tax (PAT). Revenue from operations increased from Rs 2.90 crore in FY23 to Rs 5.00 crore in FY24 and Rs 16.00 crore in FY25. PAT increased from Rs 0.28 crore in FY23 to Rs 0.82 crore in FY24 and Rs 2.61 crore in FY25.
The top customer accounted for Rs 3.66 crore (26.01 percent) of the company’s total sales for the period ended September 30, 2025; Rs 4.83 crore (30.21 percent) in FY25; Rs 1.26 crore (25.28 percent) in FY24, and Rs 0.44 crore (15.17 percent) in FY23. Any failure to retain this client or negotiate commercially viable long-term contracts, or a reduction in business from them, could adversely affect the company’s revenue, profitability, cash flows, and overall financial condition.
The top supplier accounted for Rs 5.57 crore (55.06 percent) of the company’s total purchase for the period ended September 30, 2025; Rs 4.01 crore (31.38 percent) in FY25; Rs 0.38 crore (9.68 percent) in FY24, and Rs 0.36 crore (13.55 percent) in FY23. Any inability to retain this vendor, negotiate commercially viable terms, or disruption in supplies from them could adversely affect the company’s operations, cost structure, and financial condition.
Gujarat accounted for Rs 13.54 crore (96.28 percent) of the company’s total sales for the period ended September 30, 2025; Rs 14.78 crore (92.34 percent) in FY25; Rs 4.12 crore (82.33 percent) in FY24, and Rs 2.43 crore (83.58 percent) in FY23. Furthermore, the company’s manufacturing facility is also located in this region. Any adverse political, social, regulatory, or economic developments in Gujarat, or an increase in local competition, could negatively impact the company’s business prospects, financial condition, and results of operations.
The company reported negative cash flow from operating activities amounting to Rs 0.89 crore for the period ended September 30, 2025, and Rs 2.21 crore in FY25. This was mainly due to increases in inventories, trade receivables, and other current assets. Additionally, negative cash flow from investing activities amounted to Rs 0.02 crore for the period ended September 30, 2025; Rs 0.87 crore in FY25 and Rs 0.16 crore in FY24, due to capital expenditure for its manufacturing facility. The company also reported negative cash flow from financing activities amounting to Rs 0.04 crore in FY24 and Rs 0.63 crore in FY23. This was due to interest payments and repayment of borrowings. Continued negative operating cash flows or further capex and repayment requirements could constrain liquidity, working capital funding, and future growth.
Accretion Nutraveda is reliant on demand from customers in the nutraceutical industry for a significant portion of its revenue. Any downturn in the nutraceutical industry, loss of nutraceutical customers, or a shift by customers toward developing products in-house could reduce demand for the company’s contract manufacturing services. If competitors or customers develop new products or raw materials that substitute existing offerings, or if competitors achieve lower-cost manufacturing and offer similar products at lower prices, it could adversely affect the company’s revenues and profitability.
The company, its promoters, and group companies are involved in certain ongoing legal proceedings. The company’s business prospects could be hit in case of adverse judgments in any of these cases.
Accretion Nutraveda exports products to Sri Lanka, Singapore, and the US, and its business is exposed to regulatory and compliance requirements in these jurisdictions. Failure to comply with evolving export-market regulations, licensing requirements, or product approval processes could lead to sanctions, enforced shutdowns, delays in approvals, or higher compliance costs, which could adversely affect operations and cash flows. In addition, international transactions can involve geopolitical and economic instability, foreign exchange exposure, longer payment cycles, and difficulty collecting receivables, any of which may adversely affect sales volumes, profitability, and financial condition.
As of September 30, 2025, the company had outstanding financial indebtedness of Rs 4.43 crore. Failure to service or repay these loans could harm the company’s operations and financial position.

Application details

For Accretion Nutraveda IPO, eligible investors can apply as Individual investor.

Apply asPrice bandApply rangeLot size
Individual investor₹122 - ₹129₹2 - ₹5 Lakhs1000

About

Accretion Nutraveda IPO Timetable

IPO Open Wed, Jan 28, 2026
IPO Close Fri, Jan 30, 2026
IPO Allotment Mon, Feb 2, 2026
Refund Initated Tue, Feb 3, 2026
Credit of Shares Tue, Feb 3, 2026
Listing of Shares Wed, Feb 4, 2026

Frequently Asked Questions